[1]
|
Cushing, H. (1930) Experiences with the Cerebellar Medulloblastomas: A Critical Review. Acta Pathologica Microbiologica Scandinavica, 1, 1-86. https://doi.org/10.1111/j.1600-0463.1930.tb06503.x
|
[2]
|
Kool, M., Korshunov, A., Remke, M., Jones, D.T., Schlanstein, M., Northcott, P.A., et al. (2012) Molecular Subgroups of Medulloblastoma: An International Meta-Analysis of Transcriptome, Genetic Aberrations, and Clinical Data of WNT, SHH, Group 3, and Group 4 Medulloblastoma. Acta Neuropathologica, 123, 473-484.
https://doi.org/10.1007/s00401-012-0958-8
|
[3]
|
Taylor, M.D., Northcott, P.A., Korshunov, A., Remke, M., Cho, Y.J., Clifford, S.C., et al. (2012) Molecular Subgroups of Medulloblastoma: The Current Consensus. Acta Neuropathologica, 123, 465-472.
https://doi.org/10.1007/s00401-011-0922-z
|
[4]
|
Thompson, M.C., Fuller, C., Hogg, T.L., Dalton, J., Finkelstein, D., Lau, C.C., et al. (2006) Genomics Identifies Medulloblastoma Subgroups That Are Enriched for Specific Genetic Alterations. Journal of Clinical Oncology, 24, 1924-1931. https://doi.org/10.1200/JCO.2005.04.4974
|
[5]
|
Northcott, P.A., Korshunov, A., Witt, H., Hielscher, T., Eberhart, C.G., Mack, S., et al. (2011) Medulloblastoma Comprises Four Distinct Molecular Variants. Journal of Clinical Oncology, 29, 1408-1414.
https://doi.org/10.1200/JCO.2009.27.4324
|
[6]
|
Shih, D.J., Northcott, P.A., Remke, M., Korshunov, A., Ramaswamy, V., Kool, M., Luu, B., et al. (2014) Cytogenetic Prognostication within Medulloblastoma Subgroups. Journal of Clinical Oncology, 32, 886-896.
https://doi.org/10.1200/JCO.2013.50.9539
|
[7]
|
Northcott, P.A., Shih, D.J., Remke, M., Cho, Y.J., Kool, M., Hawkins, C., et al. (2012) Rapid, Reliable, and Reproducible Molecular Sub-Grouping of Clinical Medulloblastoma Samples. Acta Neuropathologica, 123, 615-626.
https://doi.org/10.1007/s00401-011-0899-7
|
[8]
|
Northcott, P.A., Shih, D.J., Peacock, J., Garzia, L., Morrissy, A.S., Zichner, T., et al. (2012) Subgroup-Specific Structural Variation across 1,000 Medulloblastoma Genomes. Nature, 488, 49-56. https://doi.org/10.1038/nature11327
|
[9]
|
Pai Panandiker, A., Ning, H., Likhacheva, A., Ullman, K., Arora, B., Ondos, J., et al. (2007) Craniospinal Irradiation with Spinal IMRT to Improve Target Homogeneity. International Journal of Radiation Oncology, Biology, Physics, 68, 1402-1409. https://doi.org/10.1016/j.ijrobp.2007.02.037
|
[10]
|
Parker, W., Filion, E., Roberge, D. and Freeman, C.R. (2007) Intensity-Modulated Radiotherapy for Craniospinal Irradiation: Target Volume Considerations, Dose Constraints, and Competing Risks. International Journal of Radiation Oncology, Biology, Physics, 69, 251-257. https://doi.org/10.1016/j.ijrobp.2007.04.052
|
[11]
|
Millard, N.E. and De Braganca, K.C. (2016) Medulloblastoma. Journal of Child Neurology, 31, 1341-1353.
https://doi.org/10.1177/0883073815600866
|
[12]
|
Hughes, E.N., Shillito, J., Sallan, S.E., Loeffler, J.S., Cassady, J.R. and Tarbell, N.J. (1988) Medulloblastoma at the Joint Center for Radiation Therapy between 1968 and 1984. The Influence of Radiation Dose on the Patterns of Failure and Survival. Cancer, 61, 1992-1998.
https://doi.org/10.1002/1097-0142(19880515)61:10%3C1992::AID-CNCR2820611011%3E3.0.CO;2-J
|
[13]
|
del Charco, J.O., Bolek, T.W., McCollough, W.M., Maria, B.L., Kedar, A., Braylan, R.C., et al. (1998) Medulloblastoma: Time-Dose Relationship Based on a 30-Year Review. International Journal of Radiation Oncology, Biology, Physics, 42, 147-154. https://doi.org/10.1016/S0360-3016(98)00197-7
|
[14]
|
Merchant, T.E., Kun, L.E., Krasin, M.J., Wallace, D., Chintagumpala, M.M., Woo, S.Y., et al. (2008) Multi-Institution Prospective Trial of Reduced-Dose Craniospinal Irradiation (23.4 Gy) Followed by Conformal Posterior Fossa (36 Gy) and Primary Site Irradiation (55.8 Gy) and Dose-Intensive Chemotherapy for Average-Risk Medulloblastoma. International Journal of Radiation Oncology, Biology, Physics, 70, 782-787.
https://doi.org/10.1016/j.ijrobp.2007.07.2342
|
[15]
|
Lannering, B., Rutkowski, S., Doz, F., Pizer, B., Gustafsson, G., Navajas, A., et al. (2012) Hyperfractionated versus Conventional Radiotherapy Followed by Chemotherapy in Standard-Risk Medulloblastoma: Results from the Randomized Multicenter HIT-SIOP PNET 4 Trial. Journal of Clinical Oncology, 30, 3187-3193.
https://doi.org/10.1200/JCO.2011.39.8719
|
[16]
|
Packer, R.J., Goldwein, J., Nicholson, H.S., Vezina, L.G., Allen, J.C., Ris, M.D., et al. (1999) Treatment of Children with Medulloblastomas with Reduced-Dose Craniospinal Radiation Therapy and Adjuvant Chemotherapy: A Children's Cancer Group Study. Journal of Clinical Oncology, 17, 2127. https://doi.org/10.1200/JCO.1999.17.7.2127
|
[17]
|
Gajjar, A., Chintagumpala, M., Ashley, D., Kellie, S., Kun, L.E., Merchant, T.E., et al. (2006) Risk-Adapted Craniospinal Radiotherapy Followed by High-Dose Chemotherapy and Stem-Cell Rescue in Children with Newly Diagnosed Medulloblastoma (St Jude Medulloblastoma-96): Long-Term Results from a Prospective, Multicentre Trial. Lancet Oncology, 7, 813-820. Erratum in: Lancet Oncology, 7, 797. https://doi.org/10.1016/S1470-2045(06)70867-1
|
[18]
|
Packer, R.J., Siegel, K.R., Sutton, L.N., Evans, A.E., D’Angio, G., Rorke, L.B., Bunin, G.R. and Schut, L. (1988) Efficacy of Adjuvant Chemotherapy for Patients with Poor-Risk Medulloblastoma: A Preliminary Report. Annals of Neurology, 24, 503-508. https://doi.org/10.1002/ana.410240405
|
[19]
|
Packer, R.J., Sutton, L.N., Elterman, R., Lange, B., Goldwein, J., Nicholson, H.S., Mulne, L., Boyett, J., D’Angio, G., Wechsler-Jentzsch, K., et al. (1994) Outcome for Children with Medulloblastoma Treated with Radiation and Cisplatin, CCNU, and Vincristine Chemotherapy. Journal of Neurosurgery, 81, 690-698.
https://doi.org/10.3171/jns.1994.81.5.0690
|
[20]
|
Gandola, L., Massimino, M., Cefalo, G., Solero, C., Spreafico, F., Pecori, E., Riva, D., et al. (2008) Hyperfractionated Accelerated Radiotherapy in the Milan Strategy for Metastatic Medulloblastoma. Journal of Clinical Oncology, 27, 566-571. https://doi.org/10.1200/JCO.2008.18.4176
|
[21]
|
Padovani, L., Horan, G. and Ajithkumar, T. (2019) Radiotherapy Advances in Paediatric Medulloblastoma Treatment. Clinical Oncology, 31, 171-181. https://doi.org/10.1016/j.clon.2019.01.001
|
[22]
|
Rutkowski, S., Gerber, N.U., von Hoff, K., Gnekow, A., Bode, U., Graf, N., et al. (2009) Treatment of Early Childhood Medulloblastoma by Postoperative Chemotherapy and Deferred Radiotherapy. Neuro-Oncology, 11, 201-210.
https://doi.org/10.1215/15228517-2008-084
|
[23]
|
Ashley, D.M., Merchant, T.E., Strother, D., Zhou, T., Duffner, P., Burger, P.C., Miller, D.C., et al. (2012) Induction chemotherapy and Conformal Radiation Therapy for Very Young Children with Nonmetastatic Medulloblastoma: Children’s Oncology Group Study P9934. Journal of Clinical Oncology, 30, 3181-3186.
https://doi.org/10.1200/JCO.2010.34.4341
|
[24]
|
Bowers, D.C., Gargan, L., Weprin, B.E., Mulne, A.F., Elterman, R.D., Munoz, L., Giller, C.A. and Winick, N.J. (2007) Impact of Site of Tumor Recurrence Upon Survival for Children with Recurrent or Progressive Medulloblastoma. Journal of Neurosurgery, 107, 5-10. https://doi.org/10.3171/PED-07/07/005
|
[25]
|
Dunkel, I.J., Gardner, S.L., Garvin Jr., J.H., Goldman, S., Shi, W. and Finlay, J.L. (2010) High-Dose Carboplatin, Thiotepa, and Etoposide with Autologous Stem Cell Rescue for Patients with Previously Irradiated Recurrent Medulloblastoma. Neuro-Oncology, 12, 297-303. https://doi.org/10.1093/neuonc/nop031
|
[26]
|
Kadota, R.P., Mahoney, D.H., Doyle, J., Duerst, R., Friedman, H., Holmes, E., Kun, L., Zhou, T. and Pollack, I.F. (2008) Dose Intensive Melphalan and Cyclophosphamide with Autologous Hematopoietic Stem Cells for Recurrent Medulloblastoma or Germinoma. Pediatric Blood & Cancer, 51, 675-678. https://doi.org/10.1002/pbc.21655
|
[27]
|
Milker-Zabel, S., Zabel, A., Thilmann, C., Zuna, I., Hoess, A., Wannenmacher, M. and Debus, J. (2002) Results of Three-Dimensional Stereotactically-Guided Radiotherapy in Recurrent Medulloblastoma. Journal of Neuro-Oncology, 60, 227-233. https://doi.org/10.1023/A:1021184400053
|
[28]
|
Wetmore, C., Herington, D., Lin, T., Onar-Thomas, A., Gajjar, A. and Merchant, T.E. (2014) Reirradiation of Recurrent Medulloblastoma: Does Clinical Benefit Outweigh Risk for Toxicity? Cancer, 120, 3731-3737.
https://doi.org/10.1002/cncr.28907
|
[29]
|
Bakst, R.L., Dunkel, I.J., Gilheeney, S., Khakoo, Y., Becher, O., Souweidane, M.M. and Wolden, S.L. (2011) Reirradiation for Recurrent Medulloblastoma. Cancer, 117, 4977-4982. https://doi.org/10.1002/cncr.26148
|
[30]
|
Yamada, A., Moritake, H., Kamimura, S., Yamashita, S., Takeshima, H. and Nunoi, H. (2014) Proposed Strategy for the Use of High-Dose Chemotherapy with Stem Cell Rescue and Intrathecal Topotecan without Whole-Brain Irradiation for Infantile Classic Medulloblastoma. Pediatric Blood & Cancer, 61, 2316-2318.
https://doi.org/10.1002/pbc.25174
|
[31]
|
Aguilera, D., Mazewski, C., Fangusaro, J., MacDonald, T.J., McNall-Knapp, R.Y., Hayes, L.L., Kim, S. and Castellino, R.C. (2013) Response to Bevacizumab, Irinotecan, and Temozolomide in Children with Relapsed Medulloblastoma: A Multi-Institutional Experience. Child’s Nervous System, 29, 589-596.
https://doi.org/10.1007/s00381-012-2013-4
|
[32]
|
Ashley, D.M., Meier, L., Kerby, T., Zalduondo, F.M., Friedman, H.S., Gajjar, A., et al. (1996) Response of Recurrent Medulloblastoma to Low-Dose Oral Etoposide. Journal of Clinical Oncology, 14, 1922-1927.
https://doi.org/10.1200/JCO.1996.14.6.1922
|
[33]
|
Gururangan, S., Krauser, J., Watral, M.A., Driscoll, T., Larrier, N., Reardon, D.A., et al. (2008) Efficacy of High-Dose Chemotherapy or Standard Salvage Therapy in Patients with Recurrent Medulloblastoma. Neuro-Oncology, 10, 745-751. https://doi.org/10.1215/15228517-2008-044
|
[34]
|
Dunkel, I.J., Boyett, J.M., Yates, A., Rosenblum, M., Garvin Jr., J.H., Bostrom, B.C., et al. (1998) High-Dose Carboplatin, Thiotepa, and Etoposide with Autologous Stem-Cell Rescue for Patients with Recurrent Medulloblastoma. Children’s Cancer Group. Journal of Clinical Oncology, 16, 222-228. https://doi.org/10.1200/JCO.1998.16.1.222
|
[35]
|
Packer, R.J., Gajjar, A., Vezina, G., Rorke-Adams, L., Burger, P.C., Robertson, P.L., et al. (2006) Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. Journal of Clinical Oncology, 24, 4202-4208. https://doi.org/10.1200/JCO.2006.06.4980
|
[36]
|
Mizumoto, M., Murayama, S., Akimoto, T., Demizu, Y., Fukushima, T., Ishida, Y., et al. (2016) Proton Beam Therapy for Pediatric Malignancies: A Retrospective Observational Multicenter Study in Japan. Cancer Medicine, 5, 1519-1525.
https://doi.org/10.1002/cam4.743
|
[37]
|
Mizumoto, M., Murayama, S., Akimoto, T., Demizu, Y., Fukushima, T., Ishida, Y., et al. (2017) Long-Term Follow-up after Proton Beam Therapy for Pediatric Tumors: A Japanese National Survey. Cancer Science, 108, 444-447.
https://doi.org/10.1111/cas.13140
|
[38]
|
Gordon, J. and Siebers, J. (2013) Addressing a Gap in Current IMRT Quality Assurance. International Journal of Radiation Oncology, Biology, Physics, 87, 20-21. https://doi.org/10.1016/j.ijrobp.2013.03.030
|
[39]
|
Eaton, B.R., Esiashvili, N., Kim, S., Patterson, B., Weyman, E.A., Thornton, L.T., et al. (2016) Endocrine Outcomes with Proton and Photon Radiotherapy for Standard Risk Medulloblastoma. Neuro-Oncology, 18, 881-887.
https://doi.org/10.1093/neuonc/nov302
|
[40]
|
Yock, T.I., Yeap, B.Y., Ebb, D.H., Weyman, E., Eaton, B.R., Sherry, N.A., et al. (2016) Long-Term Toxic Effects of Proton Radiotherapy for Paediatric Medulloblastoma: A Phase 2 Single-Arm Study. Lancet Oncology, 17, 287-298. Erratum in: Lancet Oncology, 21, e132. https://doi.org/10.1016/S1470-2045(15)00167-9
|
[41]
|
Kahalley, L.S., Peterson, R., Ris, M.D., Janzen, L., Okcu, M.F., Grosshans, D.R., et al. (2020) Superior Intellectual Outcomes after Proton Radiotherapy Compared With Photon Radiotherapy for Pediatric Medulloblastoma. Journal of Clinical Oncology, 38, 454-461. https://doi.org/10.1200/JCO.19.01706
|
[42]
|
Brodin, N.P., Munck af Rosenschöld, P., Blomstrand, M., Kiil-Berthlesen, A., Hollensen, C., Vogelius, I.R., et al. (2014) Hippocampal Sparing Radiotherapy for Pediatric Medulloblastoma: Impact of Treatment Margins and Treatment Technique. Neuro-Oncology, 16, 594-602. https://doi.org/10.1093/neuonc/not225
|
[43]
|
Pulsifer, M.B., Sethi, R.V., Kuhlthau, K.A., MacDonald, S.M., Tarbell, N.J. and Yock, T.I. (2015) Early Cognitive Outcomes Following Proton Radiation in Pediatric Patients with Brain and Central Nervous System Tumors. International Journal of Radiation Oncology, Biology, Physics, 93, 400-407. https://doi.org/10.1016/j.ijrobp.2015.06.012
|
[44]
|
St Clair, W.H., Adams, J.A., Bues, M., Fullerton, B.C., La Shell, S., Kooy, H.M., et al. (2004) Advantage of Protons Compared to Conventional X-Ray or IMRT in the Treatment of a Pediatric Patient with Medulloblastoma. International Journal of Radiation Oncology, Biology, Physics, 58, 727-734. https://doi.org/10.1016/S0360-3016(03)01574-8
|
[45]
|
Yuh, G.E., Loredo, L.N., Yonemoto, L.T., Bush, D.A., Shahnazi, K., Preston, W., et al. (2004) Reducing Toxicity from Craniospinal Irradiation: Using Proton Beams to Treat Medulloblastoma in Young Children. Cancer Journal, 10, 386-390. https://doi.org/10.1097/00130404-200411000-00009
|
[46]
|
Guruangan, S., Dunkel, I.J., Goldman, S., Garvin, J.H., Rosenblum, M., Boyett, J.M., et al. (1998) Myeloablative Chemotherapy with Autologous Bone Marrow Rescue in Young Children with Recurrent Malignant Brain Tumors. Journal of Clinical Oncology, 16, 2486-2493. https://doi.org/10.1200/JCO.1998.16.7.2486
|
[47]
|
Eaton, B.R., Esiashvili, N., Kim, S., Weyman, E.A., Thornton, L.T., Mazewski, C., et al. (2016) Clinical Outcomes among Children with Standard-Risk Medulloblastoma Treated with Proton and Photon Radiation Therapy: A Comparison of Disease Control and Overall Survival. International Journal of Radiation Oncology, Biology, Physics, 94, 133-138. https://doi.org/10.1016/j.ijrobp.2015.09.014
|
[48]
|
Zhang, R., Howell, R.M., Giebeler, A., Taddei, P.J., Mahajan, A. and Newhauser, W.D. (2013) Comparison of Risk of Radiogenic Second Cancer Following Photon and Proton Craniospinal Irradiation for a Pediatric Medulloblastoma Patient. Physics in Medicine & Biology, 58, 807-823. https://doi.org/10.1088/0031-9155/58/4/807
|
[49]
|
Fernandes, R.R.A., Vianna, C.M.M., Guerra, R.L., Cancela, M.C., Almeida, L.M., Pereira, A.J.D.C., et al. (2019) Cost-Effectiveness of Proton versus Photon Therapy in Pediatric Medulloblastoma Treatment: A Patient Volume-Based Analysis. Value in Health Regional Issues, 20, 122-128. https://doi.org/10.1016/j.vhri.2019.03.006
|
[50]
|
Packer, R.J., Zhou, T., Holmes, E., Vezina, G. and Gajjar, A. (2013) Survival and Secondary Tumors in Children with Medulloblastoma Receiving Radiotherapy and Adjuvant Chemotherapy: Results of Children’s Oncology Group Trial A9961. Neuro-Oncology, 15, 97-103. https://doi.org/10.1093/neuonc/nos267
|
[51]
|
Khatua, S., Song, A., Citla Sridhar, D. and Mack, S.C. (2018) Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights. Current Neuropharmacology, 16, 1045-1058.
https://doi.org/10.2174/1570159X15666171129111324
|
[52]
|
von Bueren, A.O., von Hoff, K., Pietsch, T., Gerber, N.U., Warmuth-Metz, M., Deinlein, F., et al. (2011) Treatment of Young Children with Localized Medulloblastoma by Chemotherapy Alone: Results of the Prospective, Multicenter Trial HIT 2000 Confirming the Prognostic Impact of Histology. Neuro-Oncology, 13, 669-679.
https://doi.org/10.1093/neuonc/nor025
|